Home > Journals > Minerva Anestesiologica > Past Issues > Articles online first > Minerva Anestesiologica 2021 Aug 02

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Anestesiologica 2021 Aug 02

DOI: 10.23736/S0375-9393.21.15668-8

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Effect of sugammadex on the recovery of gastrointestional motility after open pancreaticoduodenectomy: a single-center retrospective study

Hye-Yeon CHO 1, Hyerin KIM 1, Susie YOON 1, 2, Ho-Jin LEE 1, 2 , Hongbeom KIM 3, 4, Hyung-Chul LEE 1, 2, Won H. KIM 1, 2, Jin‑Young JANG 3, 4

1 Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Republic of Korea; 2 Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; 3 Department of Surgery, Seoul National University Hospital, Seoul, Republic of Korea; 4 Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea


PDF


BACKGROUND: This study aimed to investigate the association between sugammadex use and the occurrence of delayed passage of first flatus and oral intake tolerance following open pancreaticoduodenectomy (PD).
METHODS: We reviewed consecutive patients who underwent open PD between 2015 and 2019; subsequently, they were divided into the sugammadex (group S) and neostigmine with anticholinergics (group N) groups based on the reversal agent used. We performed stabilized inverse probability of treatment weighting (IPTW) analysis to adjust for baseline differences between the groups. We compared the delayed passage of first flatus, oral intake tolerance, and other postoperative outcomes between the groups before and after IPTW.
RESULTS: Of the 736 included patients, 309 (42.0%) received sugammadex. Stabilized IPTW revealed a significantly lower occurrence of delayed passage of first flatus in group S (19.5%) compared to group N (27.7%) (OR 0.61, 95% CI: 0.43-0.86, P = 0.005). Further, there was a significantly lower occurrence of delayed oral intake tolerance in group S (18.9%) than in group N (28.0%) (OR 0.65, 95% CI: 0.46-0.92, P = 0.016).
CONCLUSIONS: Compared to previous reversal agents, sugammadex use was significantly associated with a decrease in the occurrence of prolonged time to first flatus and oral intake tolerance following open PD.


KEY WORDS: Gastrointestional motility; Ileus; Pancreaticoduodenectomy; Postoperative complications; Sugammadex

top of page